SUNY-Buffalo: Study - Gadolinium Deposition Occurs in Early MS But Five-Years of Follow-Up Neither Prove--Nor Rule Out--Clinical Impact
July 08, 2019
July 08, 2019
BUFFALO, New York, July 8 [TNSmedicalresearch] -- The State University of New York's Buffalo Campus issued the following news release:
A comprehensive, longitudinal study of patients with multiple sclerosis (MS) that followed patients from the time of their diagnosis for an average of five years, has found that while a commonly used imaging linear contrast agent, gadodiamide, does accumulate in the brain early in the disease, there is no discernible clinical impact.
At . . .
A comprehensive, longitudinal study of patients with multiple sclerosis (MS) that followed patients from the time of their diagnosis for an average of five years, has found that while a commonly used imaging linear contrast agent, gadodiamide, does accumulate in the brain early in the disease, there is no discernible clinical impact.
At . . .